The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs
Official Title: An International, Multicenter, Open-label Study to Evaluate Safety, Tolerability, Biodistribution, Dosimetry and Preliminary Efficacy of 177Lu-OPS201 for the Therapy of Somatostatin Receptor-positive Neuroendocrine Tumors (NETs)
Study ID: NCT02592707
Brief Summary: The purpose of this clinical phase I/II study was to investigate the safety and tolerability of satoreotide tetraxetan (177Lu-IPN01072, formerly known as 177Lu-OPS201) used for the treatment of patients with neuroendocrine tumors (NETs). The secondary objectives of this study were the assessment of biodistribution, dosimetry and preliminary efficacy of satoreotide tetraxetan.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
MD Anderson Cancer Center, Department of Nuclear Medicine, Houston, Texas, United States
Peter MacCallum Cancer Centre, Molecular Imaging and Targeted Therapeutics Laboratory, East Melbourne, , Australia
Ramsay Hollywood Private Hospital, Department of Nuclear Medicine, Perth, , Australia
University Hospital Vienna, Department of Nuclear Medicine, Vienna, , Austria
CHU de Quebec - Universite Laval Research Center, Department of Radiology and Nuclear Medicine, Québec, , Canada
University Hospital Aarhus, Department of Hepatology and Gastroenterology, Aarhus, , Denmark
CHU de Nantes, Hotel Dieu, Service de Medecine Nucleaire, Nantes, , France
University Hospital Basel, Department of Nuclear Medicine, Basel, , Switzerland
Royal Free Hospital, Department of Nuclear Medicine, London, , United Kingdom
Name: Ipsen Medical Director
Affiliation: Ipsen
Role: STUDY_DIRECTOR